Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.
The response to fosmidomycin of four strains of Escherichia coli was studied in an in vitro model of the treatment of bacterial cystitis. Three susceptible strains of E. coli responded well to relatively low concentrations of fosmidomycin: doses achieving peak concentrations of 50 or 250 mg/l suppressed bacterial growth for 13 h or more; however, when the surviving bacteria were challenged with a second dose, a reduced response was observed. When a fully resistant strain was exposed to fosmidomycin, bacterial growth was also suppressed for 13 h or more, even when the peak concentration achieved was below the conventionally determined minimum inhibitory concentration. Resistant variants which emerged after exposure to fosmidomycin were also resistant to fosfomycin in the absence of the potentiating agent, glucose-6-phosphate. In the presence of glucose-6-phosphate, complete (or partial) susceptibility to fosmidomycin and fosfomycin was retained by three of the four strains. These results suggest that fosmidomycin and fosfomycin are transported into E. coli by a similar mechanism, and that deletion of the hexose phosphate transport system does not occur following exposure to fosmidomycin in the absence of glucose-6-phosphate.
Kanimoto
Y
Y
Department of Microbiology, University Hospital, Queen's Medical Centre, Nottingham, England.
Greenwood
D
D
D003556:Cystitis / Q000188:drug therapy*; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005578:Fosfomycin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019298:Glucose-6-Phosphate; D005958:Glucosephosphates / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests
D005958:Glucosephosphates; D005578:Fosfomycin; D019298:Glucose-6-Phosphate; C024640:fosmidomycin